ALL ASN products: The ASN products are in capsule or powdered form and bear the ASN label. *********the List of ASN products********...
FDA Recall Notice
Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-2957-2015.
All ASN brand products are recalled because it was ordered by the United States District Court for the District of Oregon. Products are also recalled due to misbranded, adulterated, and unapproved new drugs because of certain claims about their effects had not been approved by the FDA.
Corrective Action (per FDA)
Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-2957-2015.
Recall terminated by FDA.
✅ What you should do
- Stop using the product if you own it.
- Check the model number, lot code, or sell-by date against the recall notice above.
- Contact James G. Cole, Inc., Dba Asn/maxam Neutraceutics or the retailer where you bought it for a refund, replacement, or repair.
- For the most current official instructions, visit the FDA recall page.
- If you've been hurt by this product, report the incident to FDA.
Consumer Contact (per FDA)
Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-2957-2015.
James G. Cole, Inc., dba ASN/Maxam Neutraceutics
About the U.S. Food and Drug Administration
The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.
Visit FDA.gov →📣 Report a food, supplement, or cosmetic problem to the FDA
If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.
James G. Cole, Inc., Dba Asn/maxam Neutraceutics Recall FAQ
James G. Cole, Inc., Dba Asn/maxam Neutraceutics is the subject of a food safety report: ALL ASN products: The ASN products are in capsule or powdered form and bear the ASN label. *********the List of ASN products********.... The notice was published on March 6, 2015 by the U.S. Food and Drug Administration (FDA). Approximately 0 units are potentially affected.